Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Biophytis ( (BPTSY) ).
Biophytis announced its successful participation at the BIO International Convention 2025, held from June 16-19 in Boston, showcasing its innovative therapies for obesity, sarcopenia, and longevity. The company highlighted its advancements in obesity pharmacotherapies, sarcopenia treatments, and longevity research, emphasizing its role in precision medicine. Post-convention, Biophytis is actively seeking strategic partnerships and collaborations to further its global commercialization efforts, reinforcing its commitment to delivering transformative treatments.
The most recent analyst rating on (BPTSY) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Biophytis stock, see the BPTSY Stock Forecast page.
Spark’s Take on BPTSY Stock
According to Spark, TipRanks’ AI Analyst, BPTSY is a Underperform.
Biophytis faces significant financial challenges, with ongoing losses and negative equity posing major risks. While there is some short-term technical strength, the long-term technical indicators and valuation metrics highlight weaknesses. The lack of substantial earnings call information increases uncertainty, contributing to a low overall score.
To see Spark’s full report on BPTSY stock, click here.
More about Biophytis
Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age-related diseases, including muscular diseases like sarcopenia and metabolic disorders such as obesity. The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil. Its lead drug candidate, BIO101, is in development for these conditions, with Phase 3 trials ready to start for sarcopenia and Phase 2 for obesity.
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.39M
Find detailed analytics on BPTSY stock on TipRanks’ Stock Analysis page.